Investigation of the relationship between IL-6 and type 2 biomarkers in patients with severe asthma

TY - JOUR

T1 - Investigation of the relationship between IL-6 and type 2 biomarkers in patients with severe asthma

AU - National Heart, Lung, and Blood Institute's Severe Asthma Research Program (SARP) Networks

AU - Li, Xingnan

AU - Hastie, Annette T.

AU - Peters, Michael C.

AU - Hawkins, Gregory A.

AU - Phipatanakul, Wanda

AU - Li, Huashi

AU - Moore, Wendy C.

AU - Busse, William W.

AU - Castro, Mario

AU - Erzurum, Serpil C.

AU - Gaston, Benjamin

AU - Israel, Elliot

AU - Jarjour, Nizar N.

AU - Levy, Bruce D.

AU - Wenzel, Sally E.

AU - Meyers, Deborah A.

AU - Fahy, John V.

AU - Bleecker, Eugene R.

N1 - Funding Information: Declaration of all sources of funding: SARP1 and SARP2 were supported by National Institutes of Health (NIH) grants HL69116 , HL69130 , HL69149 , HL69155 , HL69167 , HL69170 , HL69174 , HL69349 , UL1RR024992 , M01RR018390 , M01RR07122 , M01RR03186 , HL087665 , and HL091762 . SARP3 was funded by National Heart, Lung, and Blood Institute (NHLBI) grants U10 HL109172 , HL109168 , HL109152 , HL109257 , HL109046 , HL109250 , HL109164 , and HL109086 . Funding Information: Declaration of all sources of funding: SARP1 and SARP2 were supported by National Institutes of Health (NIH) grants HL69116, HL69130, HL69149, HL69155, HL69167, HL69170, HL69174, HL69349, UL1RR024992, M01RR018390, M01RR07122, M01RR03186, HL087665, and HL091762. SARP3 was funded by National Heart, Lung, and Blood Institute (NHLBI) grants U10 HL109172, HL109168, HL109152, HL109257, HL109046, HL109250, HL109164, and HL109086.Disclosure of potential conflict of interest: A. T. Hastie reports grants from the National Institutes of Health (NIH) and grant support from Genentech during the conduct of the study. W. W. Busse has received consulting fees from AstraZeneca, Genentech, Regeneron, Novartis, Sanofi, and GlaxoSmithKline. M. Castro receives university grant funding from the NIH, American Lung Association, and Patient-Centered Outcomes Research Institute; receives pharmaceutical grant funding from AstraZeneca, Chiesi, Novartis, GlaxoSmithKline, and Sanofi-Aventis; serves as a consultant for Genentech, Theravance, VIDA, TEVA, and Sanofi-Aventis; serves as a speaker for AstraZeneca, Genentech, GlaxoSmithKline, Regeneron, Sanofi, and Teva; and receives royalties from Elsevier. S. E. Wenzel has consulted for AstraZeneca, Genentech, GlaxoSmithKline, and Sanofi-Aventis in the last 3 years in matters unrelated to the content of this manuscript; participated in a multicenter clinical trial for AstraZeneca, GlaxoSmithKline, Novartis, and Sanofi-Aventis in the last 3 years unrelated to this manuscript; and received financial support for the last 2 years of SARP from an unrestricted grant from Boehringer Ingelheim. E. R. Bleecker has performed clinical trials through his employer, Wake Forest School of Medicine, and the University of Arizona for AstraZeneca, MedImmune, Boehringer Ingelheim, Genentech, Novartis, Regeneron, and Sanofi Genzyme and has also served as a paid consultant for ALK-Abelló, AstraZeneca, MedImmune, GlaxoSmithKline, Novartis, Regeneron, Sanofi Genzyme, and TEVA outside the submitted work. The rest of the authors declare that they have no relevant conflicts of interest.

PY - 2020/1

Y1 - 2020/1

UR - http://www.scopus.com/inward/record.url?scp=85073055638&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073055638&partnerID=8YFLogxK

U2 - 10.1016/j.jaci.2019.08.031

DO - 10.1016/j.jaci.2019.08.031

M3 - Article

C2 - 31513878

AN - SCOPUS:85073055638

SN - 0091-6749

VL - 145

SP - 430

EP - 433

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

IS - 1

ER -